16:28:02 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2025-03-04 Bokslutskommuniké 2024
2024-11-05 Kvartalsrapport 2024-Q3
2024-08-13 Kvartalsrapport 2024-Q2
2024-05-15 Ordinarie utdelning CMOTEC B 0.00 SEK
2024-05-14 Årsstämma 2024
2024-05-07 Kvartalsrapport 2024-Q1
2024-03-05 Bokslutskommuniké 2023
2023-10-17 Kvartalsrapport 2023-Q3
2023-08-15 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-17 Ordinarie utdelning CMOTEC B 0.00 SEK
2023-05-16 Årsstämma 2023
2023-03-07 Bokslutskommuniké 2022
2022-11-22 Kvartalsrapport 2022-Q3
2022-08-16 Kvartalsrapport 2022-Q2
2022-05-25 Ordinarie utdelning CMOTEC B 0.00 SEK
2022-05-24 Årsstämma 2022
2022-05-03 Kvartalsrapport 2022-Q1
2022-03-08 Bokslutskommuniké 2021
2021-11-02 Kvartalsrapport 2021-Q3
2021-08-17 Kvartalsrapport 2021-Q2
2021-05-25 Ordinarie utdelning CMOTEC B 0.00 SEK
2021-05-24 Årsstämma 2021
2021-05-04 Kvartalsrapport 2021-Q1
2021-03-08 Bokslutskommuniké 2020
2020-11-11 Kvartalsrapport 2020-Q3
2020-08-18 Kvartalsrapport 2020-Q2
2020-05-20 Ordinarie utdelning CMOTEC B 0.00 SEK
2020-05-19 Årsstämma 2020
2020-05-13 Kvartalsrapport 2020-Q1
2020-02-28 Bokslutskommuniké 2019
2019-11-12 Kvartalsrapport 2019-Q3
2019-08-12 Kvartalsrapport 2019-Q2
2019-05-09 Ordinarie utdelning CMOTEC B 0.00 SEK
2019-05-08 Kvartalsrapport 2019-Q1
2019-05-08 Årsstämma 2019
2019-03-19 Extra Bolagsstämma 2019
2019-02-14 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-15 Kvartalsrapport 2018-Q2
2018-05-15 Kvartalsrapport 2018-Q1
2018-05-15 Extra Bolagsstämma 2018
2018-03-01 Ordinarie utdelning CMOTEC B 0.00 SEK
2018-02-28 Årsstämma 2018
2018-01-30 Bokslutskommuniké 2017
2017-05-31 Extra Bolagsstämma 2017

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Scandinavian ChemoTech är ett forsknings- och utvecklingsbolag som har tagit fram teknologin Tumörspecifik Elektroporation – TSE™ för behandling av olika cancerformer. Teknologin innebär att man skickar elektroniska pulser till det behandlade området och öppnar tumörcellernas membran för att nå deras DNA. Utöver sin verksamhet i Sverige är bolaget även aktivt i Sydostasien och Indien. Scandinavian ChemoTech grundades 2015 och har sitt huvudkontor i Lund.
2022-05-26 13:41:09

Today the ESVONC congress in Syracuse, Italy, opens. In a poster, presented at the congress, the Tumour Specific Electroporation - TSE™ treatment of a horse is outlined and described as showing outstanding results.

The author of this poster is DVM (Doctor in Veterinary Medicine) Majbritt M E Larsen, Specialist in small animal internal medicine and head of Oncology at Evidensia Specialistdjursjukhuset Helsingborg.

The title of the poster is: "Treatment of equine sarcoids using intratumoral Bleomycin in combination with Tumour Specific Electroporation - TSE™" and describes the outstanding result of treatment of a 15-year-old horse with 9 sarcoids. The horse was treated once and is now in complete remission.

Surgery on sarcoids gives often only a short-term solution as the sarcoids usually returns and may also spread to new places. Sarcoids are a skin tumour that is locally invasive but does not spread to other organs, it is a fibrosarcoma and account for 40 percent of all equine cancers.

"Complete remission was achieved in 9/9 sarcoids within the current observation period of 30 weeks. Toxicity was limited, with two lesions exhibiting grade 3 toxicity and seven lesions exhibiting grade 1-2 toxicity." - writes DVM Majbritt M E Larsen in the poster

"We are very happy with this result which gives many horse owners an effective and easy treatment, to a disease that is known to be difficult to treat."-says Elin Wallin Product specialist at Vetiqure AB

The complete poster will be published on Scandinavian ChemoTech's and Vetiqure's respective websites after the congress.

For more information, please contact:

Mohan Frick, CEO

+46 (0)10-218 93 00

info@chemotech.se

Certified Adviser: Erik Penser Bank, Tel: Corporate Finance AB, Tel: +46 8-463 80 00,

E-mail:certifiedadviser@penser.se

Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se

.